Edgewise Therapeutics CMO Joanne Donovan sells $38,839 in common stock
Joanne M. Donovan, Chief Medical Officer at Edgewise Therapeutics, sold 854 shares of common stock for $38,839 on November 16, 2026. This transaction was related to shares acquired through an employee stock purchase plan, and she now beneficially owns 8,139 shares. The article also highlights recent positive analyst actions and strategic developments for Edgewise Therapeutics, including price target increases and progress in clinical trials for its cardiovascular disease treatments.
Form 4 Edgewise Therapeutics Inc: Joanne M. Donovan (CMO) For: 16 November
This article reports on a Form 4 filing for Edgewise Therapeutics Inc, specifically detailing an action involving Joanne M. Donovan, the Chief Medical Officer (CMO), on November 16. The report is published by Investing.com and includes the stock symbol EWTX. No further details about the transaction are provided in the article.
After selling 854 shares, Edgewise Therapeutics (EWTX) CMO Joanne M. Donovan held 8,139 shares directly.
Edgewise Therapeutics (EWTX) Chief Marketing Officer Joanne M. Donovan reported the direct sale of 854 common shares on November 16, 2026, at a price of $45.48 per share, executed under a Rule 10b5-1 trading plan. Following this transaction, Donovan directly held 8,139 shares, which included 368 shares purchased on the same day through the company's 2021 Employee Stock Purchase Plan. The sold shares were originally acquired via the same Employee Stock Purchase Plan on May 15, 2025.
Form 144 EDGEWISE THERAPEUTICS INC For: 16 November By Investing.com
This article announces the filing of Form 144 for Edgewise Therapeutics Inc. (EWTX) on November 16, 2026. Form 144 indicates an intent to sell restricted or control securities. The stock symbol EWTX is noted to have decreased by 4.90% at the time of publication.
A 7.3M-share stake in Edgewise Therapeutics (EWTX) sits in client-managed portfolios.
Janus Henderson Group Ltd. has reported a deemed beneficial ownership of 7,298,521 common shares, representing 6.7% of Edgewise Therapeutics, Inc. (EWTX). These shares are held in client-managed portfolios, with Janus Henderson's asset managers exercising shared voting and dispositive power. The filing, an amended passive investment disclosure (SCHEDULE 13G/A), indicates that the Managed Portfolios, not Janus Henderson, have the right to receive dividends and sale proceeds.
Form 4 Edgewise Therapeutics Inc: Michael Nofi (CFO) For: 10 November By Investing.com
This article reports on a Form 4 filing for Edgewise Therapeutics Inc, specifically noting a transaction by Michael Nofi, the Chief Financial Officer. The filing is dated November 10. The article is a brief announcement from Investing.com.
A 4,442-share tax sale by Edgewise Therapeutics (EWTX) CFO Michael Nofi was not discretionary.
Edgewise Therapeutics CFO Michael Nofi sold 4,442 shares of the company's common stock at an average price of $45.427 per share. This sale was non-discretionary and executed to cover statutory tax withholding obligations tied to the vesting of 10,937 restricted stock units. Following the transaction, Nofi holds 32,813 restricted stock units and 6,495 common shares directly.
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
Edgewise Therapeutics (EWTX) management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, starting at 8:00 am ET. A webcast will be available on the company’s Events & Presentations page, with a replay accessible for a limited time afterward. The company is a clinical-stage cardiovascular biopharmaceutical company focused on developing therapies for cardiac equilibrium.
/C O R R E C T I O N - Edgewise Therapeutics/
Edgewise Therapeutics has issued a corrected press release regarding its upcoming investor conferences. The correction clarifies that the company will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 8:00 am ET, but removes the 2026 Truist Biopharma Symposium from its schedule. This event is considered a routine investor-relations update without new financial disclosures.
Edgewise Therapeutics gains amid report of takeover interest
Edgewise Therapeutics (EWTX) stock jumped 12% following a report that the biopharmaceutical firm has attracted takeover interest. Traders cited a Betaville "uncooked" alert suggesting the company hired advisers for a sales process, with two European pharmas and one US-listed company reportedly involved. This comes after Edgewise rose 3.6% on Thursday after reporting its Q3 results.
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
Edgewise Therapeutics submitted its STRATUS-HCM Phase 3 protocol for EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy (HCM), following a productive End-of-Phase 2 meeting with the FDA. The Phase 3 protocol introduces a tolerability-based dose escalation plan, eliminating the need for echocardiograms to guide dosing decisions, thereby reducing monitoring burden. The trial, expected to start in Q4 2026, will enroll approximately 600 adults across obstructive and nonobstructive HCM populations, with peak oxygen consumption as the primary endpoint.
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
Edgewise Therapeutics announced positive outcomes from its End-of-Phase 2 meeting with the FDA for EDG-7500, a treatment for hypertrophic cardiomyopathy (HCM). The company has submitted its Phase 3 protocol, STRATUS-HCM, which features a tolerability-based dose escalation plan that does not require echocardiograms for dosing decisions, aiming to reduce monitoring burden for patients and physicians. The global Phase 3 trial, set to begin in Q4 2026, will enroll approximately 600 adults with symptomatic obstructive and nonobstructive HCM, with peak oxygen consumption as the primary endpoint.
Edgewise Therapeutics, Inc. (EWTX) Tops Q3 EPS by 1018c
Edgewise Therapeutics, Inc. (EWTX) announced its Q3 earnings per share (EPS) of $9.65, significantly surpassing the analyst estimate of ($0.53) by $10.18. The company's stock price was up 3.57% on the day, trading at $38.87. This news provides key financial performance data for investors and analysts tracking EWTX.
A drug sale fueled Edgewise Therapeutics (EWTX) profit, but the sold drug missed trial endpoints.
Edgewise Therapeutics reported a significant net income of $1.17 billion for Q3 2026, primarily driven by the sale of its sevasemten muscular dystrophy program to Servier for $1.396 billion in upfront cash. However, Servier later announced that the pivotal GRAND CANYON study of sevasemten in Becker muscular dystrophy missed its primary and secondary endpoints, potentially impacting Edgewise's eligibility for up to $1.1 billion in future milestone payments. Edgewise is now focusing on its cardiovascular pipeline, with a Phase 3 trial planned for EDG-7500 and a Phase 2 trial underway for EDG-15400.
Two new Edgewise hires received rights to buy 17,250 shares and awards covering 8,626 more.
Edgewise Therapeutics (EWTX) granted inducement stock options for 17,250 shares and restricted stock units (RSUs) for 8,626 shares to two new non-executive employees on October 30, 2026. The options have an exercise price of $38.90 per share, equal to the grant-date closing price. Both awards are subject to continued service and specific vesting schedules, and were issued under the 2024 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Becker Muscular Dystrophy Pipeline 2026: Therapeutic Candidates, Clinical Trial Insights, and Companies Leading Drug Development | Epirium Bio, Immuno Forge, Italfarmaco, Santhera Pharma, Edgewise
DelveInsight's report details the Becker Muscular Dystrophy (BMD) pipeline, highlighting 8+ companies developing therapeutic candidates. Key players like Epirium Bio, Immuno Forge, and Edgewise Therapeutics are advancing therapies such as EPM-01, PF1801, Givinostat, Vamorolone, and EDG 5506. Recent clinical trial updates include Edgewise's Phase III-enabling GRAND CANYON study for sevasemten and ReveraGen BioPharma's completed Phase II pilot study for vamorolone.
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $59
RBC Capital has reiterated its Buy rating for Edgewise Therapeutics (EWTX.US) and maintained its target price at $59. This indicates a continued positive outlook from the firm regarding the biotechnology company's stock.
Edgewise Therapeutics, Inc. Estimates – NASDAQ:EWTX
This page on TradingView provides financial estimates and actuals for Edgewise Therapeutics, Inc. (NASDAQ: EWTX). Users can explore reported financial data and analyst estimates across various statements, compare actual results with estimates, and visualize trends over time. The platform offers access to income statement, balance sheet, cash flow, annual, and quarterly data.
William Blair initiates Edgewise Therapeutics stock with outperform rating By Investing.com
William Blair has initiated coverage on Edgewise Therapeutics (NASDAQ: EWTX) with an outperform rating and a $53 per share DCF-adjusted valuation. The company, which trades at $38.20 and has seen a 149% increase over the past year, holds significant cash reserves and is focusing on cardiovascular disease with lead assets EDG-7500 and EDG-15400. Key catalysts include Phase III initiation, 48-week Phase II EDG-7500 data, and Phase II EDG-15400 data, though clinical and regulatory setbacks remain risks.
William Blair Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $53
William Blair has initiated coverage of Edgewise Therapeutics (EWTX.US) with a Buy rating. The firm has set a price target of $53 for the company's shares. This initiation suggests a positive outlook on Edgewise Therapeutics' future performance.
William Blar Initiates Coverage on Edgewise Therapeutics With Outperform Rating
William Blar initiated coverage on Edgewise Therapeutics (EWTX) with an "Outperform" rating. The company currently holds an average "buy" rating and a mean price target of $50.46, according to MT Newswires. The article is a premium content piece requiring a subscription for full access.
William Blair initiates Edgewise Therapeutics stock with outperform rating
William Blair has initiated coverage of Edgewise Therapeutics (NASDAQ:EWTX) with an outperform rating and a DCF-adjusted valuation of $53 per share. The company, which recently sold its muscular dystrophy business for $1.55 billion, is now focusing on cardiovascular disease with lead assets EDG-7500 and EDG-15400 in clinical trials. William Blair anticipates several catalysts, including Phase III initiation for EDG-7500 and data readouts for EDG-7500 and EDG-15400 in 2027.
William Blair initiates Edgewise Therapeutics stock with outperform rating By Investing.com
William Blair has initiated coverage on Edgewise Therapeutics (NASDAQ: EWTX) with an outperform rating, setting a DCF-adjusted valuation of $53 per share, while the stock currently trades at $38.20. The company, which focuses on cardiovascular disease after selling its muscular dystrophy business, holds significant cash and has several clinical candidates in its pipeline, including EDG-7500 and EDG-15400. Potential catalysts include upcoming Phase III initiations and data readouts for its lead assets in late 2026 and 2027.
H.C. Wainwright reiterates Edgewise Therapeutics stock rating at buy By Investing.com
H.C. Wainwright has reiterated its Buy rating and $57.00 price target for Edgewise Therapeutics (NASDAQ:EWTX). This reaffirmation comes after the company presented promising Phase 1 data for its investigational drug EDG-15400 at a scientific meeting. The stock has seen significant growth over the past year, though it experienced a recent dip, and InvestingPro analysis suggests it may be oversold despite strong long-term momentum.
H.C. Wainwright reiterates Edgewise Therapeutics stock rating at buy By Investing.com
H.C. Wainwright has reaffirmed its Buy rating and $57.00 price target for Edgewise Therapeutics (NASDAQ: EWTX) following the company's presentation of positive Phase 1 data for its investigational drug EDG-15400. The drug, designed to treat heart failure with preserved ejection fraction, demonstrated rapid absorption and favorable once-daily dosing. Despite recent stock fluctuations, Edgewise Therapeutics has seen a significant 147% surge over the past year.
Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $51
Piper Sandler has reaffirmed its Buy rating for Edgewise Therapeutics (EWTX.US) and maintained its price target at $51. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
(EWTX) Movement as an Input in Quant Signal Sets
This article analyzes Edgewise Therapeutics Inc. (NASDAQ: EWTX) using AI-generated quantitative signals. It highlights weak near and mid-term sentiment but a strong long-term outlook, with specific trading strategies (Long, Momentum Breakout, Short) and risk parameters provided. The analysis includes support and resistance levels across different time horizons, indicating potential challenges despite a positive long-term view.
Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Edgewise Therapeutics (EWTX)
Analysts from H.C. Wainwright have issued bullish ratings for two healthcare stocks: Argenx Se (ARGX) and Edgewise Therapeutics (EWTX). Argenx Se received a Buy rating with a $1202.00 price target, and Edgewise Therapeutics also received a Buy rating with a $57.00 price target, both implying significant upside potential according to analyst consensus. These recommendations come amidst generally optimistic sentiments in the Healthcare sector.
Edgewise doses first patient in heart failure trial
Edgewise Therapeutics Inc. has dosed the first patient in its Phase 2 EQUINOX-HFpEF clinical trial for EDG-15400, targeting adults with symptomatic heart failure with preserved ejection fraction. The trial aims to assess the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in approximately 90 participants. EDG-15400 is an oral, selective cardiac sarcomere modulator designed to improve impaired cardiac relaxation, a key characteristic of HFpEF.
Edgewise Therapeutics starts Phase 2 trial of EDG-15400 for heart failure with preserved ejection fraction (HFpEF).
Edgewise Therapeutics has initiated its Phase 2 EQUINOX-HFpEF trial, dosing the first patient with EDG-15400, an oral drug designed to improve cardiac relaxation in adults with symptomatic heart failure with preserved ejection fraction (HFpEF). The trial aims to assess the drug's safety, tolerability, and efficacy in approximately 90 patients over 12 weeks, targeting the underlying diastolic dysfunction of this condition. Results and trial design are slated for presentation at the HFSA 2026 meeting in October.
A quarterly stock award gives director Fox 308 shares of Edgewise Therapeutics (EWTX).
Edgewise Therapeutics director Jonathan C. Fox acquired 308 shares of common stock through restricted stock units on October 1, 2026, as a Quarterly Retainer Award. Following this transaction, his direct holdings increased to 25,141 shares. This insider trade is noted as neutral in sentiment and relates to the company's Outside Directors Compensation Policy.
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics announced it granted inducement stock options to purchase 7,500 shares and restricted stock units (RSU awards) for 3,751 shares of its common stock to three new non-executive employees. These grants were made on September 30, 2026, under the company's 2024 Inducement Equity Incentive Plan, with specific vesting schedules for both the stock options and RSU awards. The grants are intended to be a material inducement for the new employees to join the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
(EWTX) Risk Channels and Responsive Allocation
This article from Stock Traders Daily analyzes Edgewise Therapeutics Inc. (NASDAQ: EWTX), highlighting weak near and mid-term sentiment despite a long-term positive outlook. The analysis provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis showing support and resistance levels. The report emphasizes elevated downside risk due to a lack of additional long-term support signals.
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics announced the grant of inducement stock options and restricted stock units to three new non-executive employees on September 30, 2026. These grants, totaling 7,500 shares in stock options and 3,751 shares in RSUs, were made under the company's 2024 Inducement Equity Incentive Plan, with specific vesting schedules tied to continued employment. The grants are intended to incentivize the new hires to join Edgewise Therapeutics, a clinical-stage biopharmaceutical company focused on cardiovascular diseases.
Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says
Oppenheimer suggests that Edgewise Therapeutics (EWTX) could gain a significant advantage from the distinctive drug profile of its compound, EDG-7500. The article is very short and implies that a premium subscription is required to read the full details of this analysis.
Edgewise Therapeutics Down Over 9%, on Pace for Largest Percent Decrease Since December 2025 -- Data Talk
Edgewise Therapeutics (EWTX) shares are down over 9% and are on track for their largest percentage decrease since December 2025. The stock is currently trading at $13.78, reflecting a 9.39% decline from its previous close. This movement comes during a period where the Nasdaq is also seeing declines.
H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $57
H.C. Wainwright has reiterated its Buy rating for Edgewise Therapeutics (EWTX.US), maintaining a target price of $57. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Edgewise unveils mechanism of action for heart drug EDG-7500
Edgewise Therapeutics announced preclinical data for EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy, showing improved cardiac relaxation without affecting systolic function in models and early clinical observations. The company plans to initiate a Phase 3 trial in Q4 2026 for the investigational oral drug, which is designed to address excessive contraction and thickening of the heart's left ventricular wall.
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 - Slideshow (NASDAQ:EWTX) 2026-09-22
Edgewise Therapeutics, Inc. (EWTX) has published a slide deck discussing the differentiated mechanism of action of its cardiac sarcomere modulator, EDG-7500. This slideshow provides insight into the company's research and development in this area. The information was released on September 22, 2026.
EWTX: EDG-7500 improves cardiac relaxation in HCM and advances to Phase 3 after positive Phase 2 data
Edgewise Therapeutics' (EWTX) EDG-7500, a cardiac sarcomere modulator, has shown positive results in improving cardiac relaxation and safety in both preclinical and Phase 2 studies for hypertrophic cardiomyopathy. Following these favorable outcomes, the company plans to initiate a Phase 3 trial for EDG-7500 in late 2026. This development suggests a significant step forward in the treatment of HCM.
Edgewise screened more than 7,000 candidates for a heart treatment. EDG-7500 improved relaxation in early tests.
Edgewise Therapeutics (EWTX) announced details regarding its cardiac sarcomere modulator, EDG-7500, a first-in-class treatment targeting the regulatory light chain (RLC) for symptomatic heart failure. Preclinical studies and early clinical observations showed EDG-7500 improves cardiac relaxation while maintaining systolic function. The company screened over 7,000 RLC candidates to identify this molecule, and is preparing to initiate a Phase 3 trial in Q4 2026.
Edgewise Therapeutics unveils EDG-7500, a new drug improving heart relaxation in hypertrophic cardiomyopathy patients.
Edgewise Therapeutics announced promising preclinical and early clinical results for EDG-7500, a novel cardiac drug designed to improve heart relaxation in patients with symptomatic hypertrophic cardiomyopathy (HCM) without impairing contraction. The company plans to initiate a Phase 3 trial in late 2026 following successful Phase 2 trial outcomes. This first-in-class treatment targets the Regulatory Light Chain and aims to address the genetic heart disease.
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
Edgewise Therapeutics announced the differentiated mechanism of action (MoA) of its cardiac sarcomere modulator EDG-7500, which targets the Regulatory Light Chain (RLC). Preclinical models show EDG-7500 improves cardiac relaxation while preserving systolic function and cardiac reserve, with early clinical observations in hypertrophic cardiomyopathy (HCM) patients supporting these findings. The company is hosting a webcast to discuss these data and expects to initiate a Phase 3 trial in Q4 2026 for EDG-7500, an investigational oral therapy for HCM.
HC Wainwright & Co. maintains Buy rating on Edgewise Therapeutics, $57 price target
HC Wainwright & Co. has reiterated its Buy rating for Edgewise Therapeutics (EWTX), setting a price target of $57.00, which suggests a 25.8% upside from the Sep 18 closing price. The key factors influencing this positive outlook are strong Phase 2 clinical data for EDG-7500 in hypertrophic cardiomyopathy and enhanced financial stability due to a $1.55 billion upfront payment from the Servier transaction, reducing financing risks.
Biotech Options Buzz: UTHR, NMRA, EWTX
The article highlights unusual options activity in biotech stocks United Therapeutics (UTHR), Neumora Therapeutics (NMRA), and Edgewise Therapeutics (EWTX). UTHR saw balanced call and put activity after its CEO's family trust sold shares. NMRA experienced high put volume as it hit 52-week lows, while EWTX saw heavy call volume despite a slight dip from its all-time high.
Edgewise Therapeutics stock hits all-time high at 48.41 USD By Investing.com
Edgewise Therapeutics Inc. stock has reached an all-time high of $48.41, marking a significant 1-year surge of 208.11%. This milestone follows the company's sale of its muscular dystrophy business to Servier for up to $2.65 billion and positive analyst coverage from Oppenheimer, Guggenheim, and RBC Capital. Despite the rapid growth, InvestingPro's Fair Value analysis suggests the stock may be overvalued.
Edgewise Therapeutics stock hits all-time high at 48.41 USD
Edgewise Therapeutics Inc. (EWTX) stock reached an all-time high of $48.41, reflecting a 208.11% one-year change and a 227% actual return. This surge follows the company's sale of its muscular dystrophy business for up to $2.65 billion and positive analyst coverage with raised price targets from Oppenheimer, Guggenheim, and RBC Capital. InvestingPro data suggests the stock might be overvalued but notes its proximity to a 52-week high, underscoring strong market interest.
CIRRUS-HCM: EDG-7500 Improves LVOT, NYHA Class in oHCM and nHCM
The CIRRUS-HCM trial demonstrated that EDG-7500, a novel cardiac sarcomere modulator, significantly improved left ventricular outflow tract (LVOT) gradients and New York Heart Association (NYHA) functional class in patients with both obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) over 12 weeks. The treatment maintained systolic function without clinically meaningful changes in left ventricular ejection fraction (LVEF) and was well-tolerated. These positive Phase 2 results support the drug's continued development and readiness for Phase 3 trials by late 2026.
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics announced it granted inducement stock options and restricted stock units to four new non-executive employees on August 31, 2026. These grants, totaling 21,000 shares for stock options and 10,501 shares for RSU awards, were made under the company's 2024 Inducement Equity Incentive Plan. The awards are intended to induce these employees to join Edgewise, in compliance with Nasdaq Listing Rule 5635(c)(4).
The Technical Signals Behind (EWTX) That Institutions Follow
This article analyzes Edgewise Therapeutics Inc. (NASDAQ: EWTX) based on AI-generated technical signals. It highlights weak near-term sentiment potentially challenging long-term strength, with resistance being tested. The analysis provides specific risk-reward setups, institutional trading strategies for various risk profiles, and a multi-timeframe signal analysis, suggesting choppy conditions due to divergent sentiment.